![Aptamers as quality control tool for production, storage and biosimilarity of the anti-CD20 biopharmaceutical rituximab | Scientific Reports Aptamers as quality control tool for production, storage and biosimilarity of the anti-CD20 biopharmaceutical rituximab | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-018-37624-1/MediaObjects/41598_2018_37624_Fig1_HTML.png)
Aptamers as quality control tool for production, storage and biosimilarity of the anti-CD20 biopharmaceutical rituximab | Scientific Reports
![Results of middle-down analysis of rituximab digested with GingisKHAN... | Download Scientific Diagram Results of middle-down analysis of rituximab digested with GingisKHAN... | Download Scientific Diagram](https://www.researchgate.net/publication/325731561/figure/fig2/AS:673332303237124@1537546339690/Results-of-middle-down-analysis-of-rituximab-digested-with-GingisKHAN-without-reduction.png)
Results of middle-down analysis of rituximab digested with GingisKHAN... | Download Scientific Diagram
![An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab - ScienceDirect An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419641116-gr1.jpg)
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab - ScienceDirect
![Cellular and molecular signal transduction pathways modulated by rituximab ( rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention | Oncogene Cellular and molecular signal transduction pathways modulated by rituximab ( rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention | Oncogene](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.onc.1208349/MediaObjects/41388_2005_Article_BF1208349_Fig1_HTML.jpg)
Cellular and molecular signal transduction pathways modulated by rituximab ( rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention | Oncogene
![Molecules | Free Full-Text | Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human Plasma Molecules | Free Full-Text | Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human Plasma](https://www.mdpi.com/molecules/molecules-26-01383/article_deploy/html/images/molecules-26-01383-g001.png)
Molecules | Free Full-Text | Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human Plasma
![Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy](https://www.frontiersin.org/files/Articles/359740/fonc-08-00163-HTML/image_m/fonc-08-00163-g001.jpg)
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy
![Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy](https://www.frontiersin.org/files/Articles/359740/fonc-08-00163-HTML/image_m/fonc-08-00163-g003.jpg)
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy
![DNA sequencing reveals mechanisms of treatment resistance in patients with diffuse large B cell lymphoma | Genome Sciences Centre DNA sequencing reveals mechanisms of treatment resistance in patients with diffuse large B cell lymphoma | Genome Sciences Centre](https://www.bcgsc.ca/sites/default/files/styles/full_article/public/2020-07/DLBCL%20R-CHOP.png?itok=hOjz3ynZ)